

**AMENDMENTS TO THE CLAIMS**

1. (Original) A nerve cell differentiation induction drug containing a Synoviolin expression inhibitor.
2. (Original) The inducing drug as claimed in Claim 1 wherein the Synoviolin expression inhibitor is siRNA or shRNA against genes coding Synoviolin.
3. (Original) The inducing drug as claimed in Claim 2 wherein the gene coding Synoviolin contains a base sequence shown in SEQ ID No. 1 or No. 2.
4. (Original) The inducing drug as claimed in Claim 2 wherein siRNA targets a portion of the sequence in the base SEQ ID No. 1 and No. 2.
5. (Original) The inducing drug as claimed in Claim 4 wherein a portion of the sequence has a base sequence shown in SEQ ID No. 3 or No. 4.
6. (Original) The inducing drug as claimed in Claim 1 wherein the Synoviolin expression inhibitor is a decoy nucleic acid that inhibits the promoter activity by binding to transcription factor of the promoter of the Synoviolin gene.
7. (Original) The inducing drug as claimed in Claim 6 wherein the decoy nucleic acid is a decoy nucleic acid shown below in (a) or (b).
  - (a) Decoy nucleic acids consisting of a base sequence indicated by SEQ ID No. 6 or No. 7.
  - (b) Decoy nucleic acids consisting of a base sequence after deleting 1 or several bases, substituting or adding base sequences in the base sequence indicated by SEQ ID No. 6 or No. 7 and having a function of inhibiting Synoviolin gene promoter activity.
8. (Original) The inducing drug as claimed in Claim 6 wherein the decoy nucleic acid is a decoy nucleic acid shown below in (a) or (b).
  - (a) Decoy nucleic acids consisting of a base sequence indicated by SEQ ID No. 6 and No. 7.

(b) Decoy nucleic acids consisting of a base sequence after deleting 1 or several bases, substituting or adding base sequences in the base sequence indicated by SEQ ID No. 6 and No. 7 and having a function of inhibiting Synoviolin gene promoter activity.

9. (Original) The inducing drug as claimed in Claim 1 wherein the Synoviolin expression inhibitor is an antisense oligonucleotide against the gene coding Synoviolin.

10. (Original) The inducing drug as claimed in Claim 9 wherein the gene coding Synoviolin contains a base sequence shown in SEQ ID No. 1 or No. 2.

11. (Original) The inducing drug as claimed in Claim 9 wherein the antisense oligonucleotide targets a portion of the sequence in the base SEQ ID No. 1 and No. 2.

12 (Cancelled). The inducing drug as claimed in one of Claims 1 through 11 for the treatment of neural disorders.

13. (Cancelled). The inducing drug as claimed in 12 wherein neural disorders include Alzheimer's disease, Parkinson's disease, peripheral nerve disorders and spinal injury.

14. (Currently amended) A method of inducing differentiation of nerve cells, comprising which is characterized by the fact that inhibiting the expression of Synoviolin is inhibited.

15. (New) A method for treating a neural disorder, comprising administering the inducing drug according to any one of Claims 1 through 11 to a subject in need thereof.

16. (New) The method of claim 15, wherein said neural disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, peripheral nerve disorders and spinal injury.